Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

1,206

Participants

Timeline

Start Date

March 24, 2007

Primary Completion Date

July 12, 2007

Study Completion Date

June 10, 2008

Conditions
InfluenzaInfluenza Vaccines
Interventions
BIOLOGICAL

H5N1 adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain)

Two doses of the GSK1562902A adjuvanted split virus vaccine, administered intramuscularly into the deltoid region of the non-dominant arm at Day 0 and Day 21.

BIOLOGICAL

H5N1 non-adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain)

Two doses of the GSK1562902A non-adjuvanted split virus vaccine, administered intramuscularly into the deltoid region of the non-dominant arm at Day 0 and Day 21.

BIOLOGICAL

H5N1 adjuvanted split virus vaccine (A/Indonesia/05/2005 strain)

Booster administration at Month 6 (and a second booster dose 21 days later for the un-adjuvanted group only) with an adjuvanted split virus pandemic influenza candidate vaccine containing the strain A/Indonesia/5/2005.

Trial Locations (6)

100

GSK Investigational Site, Taipei

112

GSK Investigational Site, Taipei

10700

GSK Investigational Site, Bangkok

529889

GSK Investigational Site, Singapore

688846

GSK Investigational Site, Singapore

Unknown

GSK Investigational Site, Hong Kong

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00449670 - Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults | Biotech Hunter | Biotech Hunter